Medindia
Medindia LOGIN REGISTER
Advertisement

Slone Partners, Where People Are Our Science®, Places G Paul Evans, PhD, as President and CEO of Velocity Clinical Research

Thursday, February 28, 2019 General News
Advertisement
Executive brings 26 years experience both running clinical research sites and managing them for contract research organizations

BOSTON, Feb. 28, 2019 /PRNewswire-PRWeb/ -- Slone Partners, North America's leading executive search firm for life sciences and diagnostics companies, announces the placement of G Paul Evans, PhD, as President and Chief Executive Officer of Velocity Clinical Research. Based at the company's headquarters in Durham, North Carolina, Dr. Evans will be responsible for setting the strategic vision, scaling teams and research sites, and delivering high-quality study data to clients while growing patient recruitment.
Advertisement

Over the past 20 years, Velocity Clinical Research's numerous clinical research sites have completed over 1,700 studies in a wide range of therapeutic areas, including allergy and immunology, Alzheimer's, biologic therapies, cardiovascular, dermatology, endocrinology and metabolism, gerontology, infectious disease, musculoskeletal disorders, neurology, neurodegenerative disorders, pain management, Parkinson's, psychiatry, respiratory, rheumatology, sleep disorders, and vaccines. With 75 direct employees at multiple sites, Velocity Clinical Research controls its own data, patient care, and outcomes - from study feasibility to patient recruitment, and from study management to database lock. The company is strategically located near target client biopharmaceutical companies and contract research organizations (CROs) in the heart of the scientific healthcare community which comprises Research Triangle.
Advertisement

Immediately prior to joining Velocity Clinical Research, Dr. Evans served as Corporate Vice President, Global Site Solutions at PAREXEL, the international life sciences CRO and consultancy. Prior to that, he served as Vice President, Global Site Management at IQVIA (formerly Quintiles and IMS Health), the world's largest life sciences CRO and healthcare IT company. He also served as Founder and Executive Director of Synexus Limited, Europe's largest site management organization (SMO). He holds a PhD in Biomedical Engineering from the University of London and immediately thereafter completed a 3-year research fellowship, managing major collaborative research projects between the university and industry. He relocated to Durham from the UK upon accepting the CEO position with Velocity Clinical Research.

Says Slone Partners CEO Leslie Loveless, "Dr. Evans' UK-based executive career in life sciences exemplifies Slone Partners' global reach and access to top executive talent. As Velocity Clinical Research grows its business in North America, Dr. Evans' experience should prove invaluable to companies seeking high quality data and to patients contributing to the approval of next generation therapies."

ABOUT SLONE PARTNERS Slone Partners delivers the leaders who build amazing healthcare organizations - People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, research, diagnostics, precision medicine and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to exceptional clients. Our full suite of services includes identifying, negotiating with, onboarding, and relocating talent, in addition to post-placement mentoring, success monitoring, and culture fit services. To learn more about Slone Partners' value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

 

SOURCE Slone Partners

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close